Every one of those 1 sits in a single category, medical-devices. Of the tracked stories, 1 of 1 also mention BioLife Solutions, the most common co-covered peer. They are better corroborated than the beat average, carrying 19 original sources each against 3.2 for the same window.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Pacira BioSciences
Every one of those 1 sits in a single category, medical-devices. Of the tracked stories, 1 of 1 also mention BioLife Solutions, the most common co-covered peer. They are better corroborated than the beat average, carrying 19 original sources each against 3.2 for the same window. Their average consequence score of 7 runs above the beat's 5.7 for that window. We currently track 1 Healthcare story that mention Pacira BioSciences, all published on February 27, 2026.
Stories tracked
1
Sources per story
19
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 29 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Pacira BioSciences. Shared-story counts are live from our verified record — not editorial picks.
The fourth quarter of 2025 revealed a decisive shift in the healthcare technology sector toward AI-integrated diagnostics and high-margin specialized therapies. Leading the charge, Butterfly Network reported record revenue growth driven by its AI-embedded strategy, while Solventum navigated its post-spin-off stabilization phase with resilient organic growth.
Pacira BioSciences is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source
link? Report a data issue.